Volv Global presented two posters at ATS 2025, in collaboration with Takeda The posters were the result of work to…
Volv Global is pleased to attend Swiss Biotech Day 2025! Meet us at Messe Basel, 5th-6th May, to find out…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Gastric (stomach) cancer remains a formidable global health challenge, ranking…
ÉPALINGES, Switzerland, March 5, 2025 /PRNewswire-PRWeb/ Volv Global expands office footprint to more than double its office space for…
On the occasion of international Rare Disease Day 2025, we are beyond thrilled to host the voice of patient advocate…
Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys…
This article is also available in French and originally published 24 Heures. Read the original article Based in Épalinges, the small…
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults…
By Volv Global SA and WODC EU contributors Executive Summary For decades, the pharmaceutical industry has faced the same…
By Christopher Rudolf, Volv Global Rare disease patients and the journey to diagnosis, treatment, and support For patients with rare…